BACKGROUND: Angiotensin-converting enzyme 2 (ACE2) cleaves angiotensin (Ang) II to generate Ang1-7, which mediates cellular actions through Mas receptors (MasR). Hypertension is accompanied by high or low circulating AngII levels and cardiac/renal injury. The purpose of this study is to explore (i) whether circulating AngII affects ACE2/MasR expressions in the hypertensive heart and kidney; and (ii) whether Ang1-7 regulates cardiac repair/remodeling responses through MasR during hypertension. METHODS: In the first portion of the study, rats received either an AngII infusion (400ng/kg/min) for 4 weeks, leading to hypertension with high circulating AngII, or an aldosterone (ALDO, 0.75 μg/h) infusion for 4 weeks, leading to hypertension with low/normal circulating AngII. Cardiac and renal ACE2/MasR expressions were examined. We found that cardiac ACE2 was increased and MasR attenuated in both AngII and ALDO groups. However, renal ACE2 and MasR remained unchanged in both AngII- and ALDO-treated animals. RESULTS: In the second portion, rats received AngII infusion with/without MasR antagonist (A779, 1mg/kg/day) for 4 weeks. The roles of MasR blockade in cardiac inflammation, fibrosis, apoptosis, and ventricular function were examined. Chronic AngII infusion caused scattered cardiac injuries, and A779 cotreatment exacerbated cardiac injury, resulting in aggravated inflammatory, fibrogenic, and apoptotic responses compared with the AngII group. Cardiac function, however, was unaltered in the AngII and A779 groups. CONCLUSIONS: ACE2 and MasR expressions in the hypertensive heart and kidney are not regulated by circulating AngII levels. Ang1-7 is involved in multiple repair responses, suggesting that therapeutic strategies aimed at administering Ang1-7 hold potential for the management of cardiac remodeling.
BACKGROUND:Angiotensin-converting enzyme 2 (ACE2) cleaves angiotensin (Ang) II to generate Ang1-7, which mediates cellular actions through Mas receptors (MasR). Hypertension is accompanied by high or low circulating AngII levels and cardiac/renal injury. The purpose of this study is to explore (i) whether circulating AngII affects ACE2/MasR expressions in the hypertensive heart and kidney; and (ii) whether Ang1-7 regulates cardiac repair/remodeling responses through MasR during hypertension. METHODS: In the first portion of the study, rats received either an AngII infusion (400ng/kg/min) for 4 weeks, leading to hypertension with high circulating AngII, or an aldosterone (ALDO, 0.75 μg/h) infusion for 4 weeks, leading to hypertension with low/normal circulating AngII. Cardiac and renal ACE2/MasR expressions were examined. We found that cardiac ACE2 was increased and MasR attenuated in both AngII and ALDO groups. However, renal ACE2 and MasR remained unchanged in both AngII- and ALDO-treated animals. RESULTS: In the second portion, rats received AngII infusion with/without MasR antagonist (A779, 1mg/kg/day) for 4 weeks. The roles of MasR blockade in cardiac inflammation, fibrosis, apoptosis, and ventricular function were examined. Chronic AngII infusion caused scattered cardiac injuries, and A779 cotreatment exacerbated cardiac injury, resulting in aggravated inflammatory, fibrogenic, and apoptotic responses compared with the AngII group. Cardiac function, however, was unaltered in the AngII and A779 groups. CONCLUSIONS:ACE2 and MasR expressions in the hypertensive heart and kidney are not regulated by circulating AngII levels. Ang1-7 is involved in multiple repair responses, suggesting that therapeutic strategies aimed at administering Ang1-7 hold potential for the management of cardiac remodeling.
Authors: Michikado Iwata; Randy T Cowling; Devorah Gurantz; Cristina Moore; Shen Zhang; Jason X-J Yuan; Barry H Greenberg Journal: Am J Physiol Heart Circ Physiol Date: 2005-07-15 Impact factor: 4.733
Authors: Jennifer Lo; Vaibhav B Patel; Zuocheng Wang; Jody Levasseur; Susan Kaufman; Josef M Penninger; Gavin Y Oudit Journal: Exp Physiol Date: 2012-06-29 Impact factor: 2.969
Authors: Shant Der Sarkissian; Justin L Grobe; Lihui Yuan; Dhruv R Narielwala; Glenn A Walter; Michael J Katovich; Mohan K Raizada Journal: Hypertension Date: 2008-02-04 Impact factor: 10.190
Authors: Fernando Pedro de Souza-Neto; Melissa Carvalho Santuchi; Mario de Morais E Silva; Maria José Campagnole-Santos; Rafaela Fernandes da Silva Journal: Curr Hypertens Rep Date: 2018-03-14 Impact factor: 5.369
Authors: Xue Liu; Yuanjian Chen; Cody W McCoy; Tieqiang Zhao; Darryl L Quarles; Min Pi; Syamal K Bhattacharya; Gwendalyn King; Yao Sun Journal: Am J Hypertens Date: 2016-08-19 Impact factor: 2.689
Authors: Jan Klimas; Michael Olvedy; Katarina Ochodnicka-Mackovicova; Peter Kruzliak; Sona Cacanyiova; Frantisek Kristek; Peter Krenek; Peter Ochodnicky Journal: J Cell Mol Med Date: 2015-03-12 Impact factor: 5.310
Authors: Wenyuan Zhao; Tieqiang Zhao; Yuanjian Chen; Fengbo Zhao; Qingqing Gu; Robert W Williams; Syamal K Bhattacharya; Lu Lu; Yao Sun Journal: PLoS One Date: 2015-08-04 Impact factor: 3.240